Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Introduction | 11 | 2 |
| GBI Research Report Guidance | 12 | 1 |
| Market Characterization | 13 | 13 |
| Total Revenues for Biologics Sales in 2009 | 13 | 4 |
| Drivers and Restraints | 17 | 1 |
| Innovation Gap in Pharmaceutical R&D: Bigger Pharmaceutical Companies are Looking at Biotechnology Innovations to Fill the Gap in Pharmaceutical R&D | 18 | 1 |
| Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics due to Lack of Patent Expiry in Recent Years | 18 | 1 |
| Huge Investments in Biotechnology R&D Resulting in Strong Product Pipeline | 18 | 1 |
| Higher Approval Rates for Biotech Products have contributed to Growth of Biotechnology Industry | 19 | 1 |
| High Unmet Needs in Life Threatening Diseases are driving the Biotechnology Market | 19 | 1 |
| Increasing Interest of Pharmaceutical Companies in Biotechnology Industry will Aid the Growth of the Biotechnology Industries | 19 | 1 |
| Strong Growth of Biologics in the Market for Cancer and Autoimmune Diseases | 19 | 1 |
| Restraints | 20 | 1 |
| High Treatment Costs and Low Patient Compliance for Biologics are Slowing down the Market | 20 | 1 |
| Threat from Biosimilars | 21 | 1 |
| Lengthy Approval Process Reduces the Product s Effective Period of Commercial Success | 21 | 1 |
| Trends | 22 | 1 |
| Development of the Monoclonal Antibodies: Many Biotech Industries are eyeing on Monoclonal Antibodies as High Profit Products | 22 | 1 |
| Biologics for Rheumatoid Arthritis and Cancer: Rheumatoid Arthritis and Cancer are Promising Therapeutic Areas for Biologics | 23 | 1 |
| Biologics for Rheumatoid Arthritis | 23 | 1 |
| Biologics for Cancer | 24 | 1 |
| Challenges | 24 | 1 |
| Challenges in the Biologics Development | 24 | 1 |
| Resources: Lack of Funding Resources has created a Big Challenge for the Biotech Industries | 25 | 1 |
| Compliance Challenge: Complex Regulation and Competition from Biosimilars is Slowing Down the Biotech Market | 25 | 1 |
| Global Biosimilars Market | 26 | 14 |
| Global Market Size and Forecasts | 26 | 1 |
| The US Biosimilars Market Size and Forecasts | 26 | 1 |
| Europe Biosimilars Market Size and Forecasts | 27 | 1 |
| Japan Biosimilars Size and Market Forecasts | 28 | 1 |
| Market Forecasts for Biosimilars | 29 | 1 |
| Human Growth Hormone Biosimilars Markets | 29 | 2 |
| Erythropoietin Biosimilars Markets | 31 | 1 |
| Granulocyte-Colony Stimulating Factor Biosimilars Markets | 32 | 2 |
| Opportunity Analysis | 34 | 1 |
| Interferon-alpha Biosimilars | 34 | 1 |
| Interferon-Beta Biosimilars | 35 | 2 |
| Insulin and Insulin Analogs Biosimilars | 37 | 2 |
| Monoclonal Antibodies | 39 | 1 |
| Therapeutic Landscape | 40 | 14 |
| Total Biologics Revenue by Drug Classes | 40 | 1 |
| Cancer Antibodies | 41 | 1 |
| Top Selling Products in Cancer Antibodies 2009 | 41 | 1 |
| TNF Alpha Antagonist | 42 | 1 |
| Top Selling Products in TNF Antagonist Biologics 2009 | 42 | 1 |
| Insulin Products | 43 | 1 |
| Top Selling Insulin Products - 2009 | 43 | 1 |
| Erythropoiesis Stimulating Agents | 44 | 1 |
| Top Selling Products in Erythropoiesis Stimulating Agents 2009 | 44 | 1 |
| Interferon Alpha and Interferon Beta | 45 | 1 |
| Top Selling Products in Interferon-Alpha - 2009 | 45 | 1 |
| Top Selling Products in Interferon-Beta - 2009 | 45 | 1 |
| Coagulation Factors | 46 | 1 |
| Top Selling Products in Coagulation Factors 2009 | 46 | 1 |
| Granulocyte-Colony Stimulating Factor | 47 | 1 |
| Top Selling Products in Granulocytes-Colony Stimulating Factors 2009 | 47 | 1 |
| Anti-Inflammatory Antibodies | 48 | 1 |
| Top Selling Products in Anti-Inflammatory Antibodies 2009 | 48 | 1 |
| Human Growth Hormone | 49 | 1 |
| Top Selling Products in Human Growth Hormone 2009 | 49 | 1 |
| Enzyme Replacement Therapy | 50 | 1 |
| Top Selling Products in Enzyme Replacement Therapy 2009 | 50 | 1 |
| Follicle Stimulating Hormone | 51 | 1 |
| Top Selling Products in Follicle Stimulating Hormone Products - 2009 | 51 | 1 |
| Antibody Products | 51 | 1 |
| Top Selling Products in Antibodies 2009 | 51 | 1 |
| Proteins &Peptides | 52 | 1 |
| Top Selling Products in Therapeutic Proteins 2009 | 52 | 1 |
| Top Selling Products in Peptides 2009 | 53 | 1 |
| Top 10 Biotechnology Companies | 54 | 98 |
| Roche/Genentech | 54 | 1 |
| Company Overview | 54 | 1 |
| Business Description | 54 | 1 |
| Revenues from Biologics | 55 | 1 |
| Drugs in Pipeline | 56 | 1 |
| Roche Phase I Product Pipeline | 56 | 1 |
| Roche. .Phase II Product Pipeline | 57 | 1 |
| Roche Phase III Product Pipeline | 57 | 3 |
| Merger &Acquisitions Deals | 60 | 1 |
| Financials | 61 | 1 |
| Ratio Analysis | 62 | 1 |
| Profitability Ratios | 62 | 1 |
| Efficiency Ratios | 62 | 1 |
| SWOT Analysis | 63 | 1 |
| Strengths | 63 | 1 |
| Weakness | 64 | 1 |
| Opportunities | 65 | 1 |
| Threats | 66 | 1 |
| Amgen Inc. | 67 | 1 |
| Company Overview | 67 | 1 |
| Business Description | 67 | 1 |
| Revenues of Biologics | 68 | 1 |
| Drugs in Pipeline | 69 | 1 |
| Amgen Inc. Phase I Product Pipeline | 69 | 1 |
| Amgen Inc. Phase II Product Pipeline | 70 | 1 |
| Amgen Inc. Phase III Product Pipeline | 71 | 1 |
| Merger and Acquisition Deals | 72 | 1 |
| Financials | 73 | 1 |
| Ratio Analysis | 74 | 1 |
| Profitability Ratios | 74 | 1 |
| Efficiency Ratios | 74 | 1 |
| SWOT Analysis | 75 | 1 |
| Strengths | 75 | 1 |
| Weaknesses | 76 | 1 |
| Opportunities | 76 | 1 |
| Threats | 76 | 1 |
| Novo Nordisk A/S | 77 | 1 |
| Company Overview | 77 | 1 |
| Business Description | 77 | 1 |
| Revenues from Biologicals | 77 | 1 |
| Biopharmaceuticals | 77 | 1 |
| Product Wise Revenue | 78 | 3 |
| Drugs in the Pipeline | 81 | 1 |
| Novo Nordisk Phase I Product Pipeline | 81 | 1 |
| Novo Nordisk Phase II Product Pipeline | 81 | 1 |
| Novo Nordisk Phase III Product Pipeline | 82 | 1 |
| Merger and Acquisition Deals | 83 | 1 |
| Financials | 83 | 1 |
| Ratio Analysis | 84 | 1 |
| Profitability Ratios | 84 | 1 |
| Efficiency Ratios | 84 | 1 |
| SWOT Analysis | 85 | 1 |
| Strengths | 85 | 1 |
| Weaknesses | 86 | 1 |
| Opportunuities | 86 | 1 |
| Threats | 86 | 1 |
| Merck Serono S.A (Merck Serono) | 87 | 1 |
| Company Overview | 87 | 1 |
| Business Overview | 87 | 1 |
| Revenues from Biological | 88 | 2 |
| Drugs in Pipeline | 90 | 1 |
| Merck Serono Phase I Product Pipeline | 90 | 1 |
| Merck Serono Phase II Product Pipeline | 90 | 1 |
| Merck Serono Phase III Product Pipeline | 91 | 2 |
| Merger and Acquisition Deals | 93 | 1 |
| Financials | 93 | 3 |
| Ratio Analysis | 96 | 1 |
| Profitability Ratios | 96 | 1 |
| Efficiency Ratios | 96 | 1 |
| SWOT Analysis | 97 | 1 |
| Strengths | 97 | 1 |
| Weaknesses | 97 | 1 |
| Opportunities | 98 | 1 |
| Threats | 98 | 1 |
| Baxter International Inc | 99 | 1 |
| Company Overview | 99 | 1 |
| Business Overview | 99 | 1 |
| Revenues from Biologics | 100 | 1 |
| Product Wise Revenue | 101 | 1 |
| Drugs in Pipeline | 102 | 1 |
| Baxter Bioscience Phase I Product Pipeline | 102 | 1 |
| Baxter Bioscience Phase II Product Pipeline | 102 | 1 |
| Baxter Bioscience Phase III Product Pipeline | 102 | 1 |
| Merger &Acquisition Deals | 103 | 1 |
| Financials | 103 | 1 |
| Ratio Analysis | 104 | 1 |
| Profitability Ratios | 104 | 1 |
| Efficiency Ratios | 105 | 1 |
| SWOT Analysis | 105 | 1 |
| Strengths | 106 | 1 |
| Weaknesses | 106 | 1 |
| Opportunities | 107 | 1 |
| Threats | 107 | 1 |
| Biogen Idec Inc. | 108 | 1 |
| Company Overview | 108 | 1 |
| Business Description | 108 | 1 |
| Product Wise Revenue | 109 | 1 |
| Drugs in Pipeline | 110 | 1 |
| Biogen Idec Inc. Phase I Product Pipeline | 110 | 1 |
| Biogen Idec Inc. Phase II Product Pipeline | 110 | 1 |
| Biogen Idec Inc. Phase III Product Pipeline | 111 | 1 |
| Merger &Acquisition Deals | 112 | 1 |
| Financials | 112 | 1 |
| Ratio Analysis | 113 | 1 |
| Profitability Ratios | 113 | 1 |
| Efficiency Ratios | 113 | 1 |
| SWOT Analysis | 114 | 1 |
| Strengths | 114 | 1 |
| Weaknesses | 115 | 1 |
| Opportunities | 115 | 1 |
| Threats | 115 | 1 |
| Genzyme Corporation | 116 | 1 |
| Company Overview | 116 | 1 |
| Business Description | 116 | 1 |
| Product Wise Revenue | 116 | 3 |
| Drugs in Pipeline | 119 | 1 |
| Genzyme - Phase I Product Pipeline | 119 | 1 |
| Genzyme - Phase II Product Pipeline | 119 | 1 |
| Genzyme - Phase III Product Pipeline | 120 | 1 |
| Merger &Acquisition Deals | 121 | 1 |
| Financials | 121 | 2 |
| Ratio Analysis | 123 | 1 |
| Profitability Ratios | 123 | 1 |
| Efficiency Ratios | 123 | 1 |
| SWOT Analysis | 124 | 1 |
| Strengths | 124 | 1 |
| Weaknesses | 125 | 1 |
| Opportunities | 125 | 1 |
| Threats | 125 | 1 |
| CSL Limited | 126 | 1 |
| Introduction | 126 | 1 |
| Business Description | 126 | 1 |
| Revenues from Biologics | 127 | 1 |
| Drugs in Pipeline | 128 | 1 |
| CSL Ltd. Phase I Product Pipeline | 128 | 1 |
| CSL Ltd. Phase II Product Pipeline | 128 | 1 |
| CSL Ltd. Phase III Product Pipeline | 128 | 1 |
| Merger &Acquisition Deals | 129 | 1 |
| Financials | 130 | 1 |
| Ratio Analysis | 131 | 1 |
| Profitability Ratios | 131 | 1 |
| Efficiency Ratios | 131 | 1 |
| SWOT Analysis | 132 | 1 |
| Strength | 132 | 1 |
| Weakness | 133 | 1 |
| Opportunities | 133 | 1 |
| Threats | 133 | 1 |
| Allergan Inc. | 134 | 1 |
| Companies Overview | 134 | 1 |
| Business Description | 134 | 1 |
| Revenue from Biologics | 134 | 1 |
| Product Wise Revenue | 134 | 3 |
| Drugs in Pipeline | 137 | 1 |
| Allergan Inc. Phase I Product Pipeline | 137 | 1 |
| Allergan Inc. Phase II Product Pipeline. | 137 | 1 |
| Allergan Inc. Phase III Product Pipeline | 138 | 1 |
| Merger &Acquisition Deals | 138 | 1 |
| Financials | 139 | 1 |
| Ratio Analysis | 140 | 1 |
| Profitability Ratios | 140 | 1 |
| Efficiency Ratios | 140 | 1 |
| SWOT Analysis | 141 | 1 |
| Strengths | 141 | 1 |
| Weaknesses | 142 | 1 |
| Opportunities | 142 | 1 |
| Threats | 143 | 1 |
| Alexion Pharmaceutical Inc | 144 | 1 |
| Companies Overview | 144 | 1 |
| Business Overview | 144 | 1 |
| Revenues from Biological | 145 | 1 |
| Product Pipeline | 145 | 1 |
| Alexion Pharmaceutical Inc. Phase I Product Pipeline | 146 | 1 |
| Alexion Pharmaceutical Inc. Phase II Product Pipeline | 146 | 1 |
| Alexion Pharmaceutical Inc. Phase III Product Pipeline | 147 | 1 |
| Merger &Acquisition Deals | 147 | 1 |
| Financials | 147 | 1 |
| Ratio Analysis | 148 | 1 |